Mallinckrodt Sells Intrathecal Therapy Business for $203 Million

Mallinckrodt, a pharmaceutical company with a worldwide presence, develops and distributes products and therapies that treat rare conditions and diseases. The company has a particular focus on neurological disorders, rheumatology and nephrology conditions and analgesics.

In early 2017, the company announced the sale of their Inthrathecal Therapy division to Piramal Critical Care, a UK subsidiary of Piramal Enterprises. Piramal acquired the division for $203 million and the sale includes all therapies still under development.

Inthratehecal Therapy division at Mallinckrodt develops and markets products to treat spactisicty caused by brain injuries. Most of the therapies are delivered through the spine using pre-filled syringes. The sale marks a shift in Mallinckrodt’s strategies.

In announcing the sale, Mark Trudeau, President and Chief Executive Officer of Mallinckrodt, said

Mallinckrodt is transforming its portfolio to become a top-performing specialty pharmaceutical company, systematically divesting non-core businesses to build upon our growth platforms in autoimmune and rare diseases and hospital therapies.

Announcement of Sale

ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue™ Therapy for the Treatment of Local Anesthetic Systemic Toxicity

ResQ Pharma Receives FDA’s ODD status for LipidRescue Therapy (LRT) for LAST and on track to file NDA in first half of 2018

Read More

Amphastar Intranasal Naloxone Delay

Amphastar Naloxone Intranasal Approval In a disappointing press release issued February 21, 2017, pharmaceutical company Amphastar announced that its New Drug Application for Intranasal Naloxone received a Complete Response Letter from the U.S. Food and Drug...
Read More

Mallinckrodt Sells Intrathecal Therapy Business for $203 Million

Mallinckrodt Sells Intrathecal Therapy Business for $203 Million Mallinckrodt, a pharmaceutical company with a worldwide presence, develops and distributes products and therapies that treat rare conditions and diseases. The company has a particular focus on...
Read More

Dignitas Interview With Paul Burton

Paul Burton, the CEO of ResQ Pharma, Inc., was interviewed by Dignitas founder, Nicholas Delgado, in a wide-ranging discussion.

Read More

ResQ Pharma’s CEO, Paul Burton to Present at Biotech Showcase

Paul Burton, the CEO of ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings is scheduled to present at Biotech Showcase as part of the J.P. Morgan 35th Annual Healthcare Conference Week in San Francisco.

Read More

ResQ Pharma Raises $725,000

ResQ Pharma, Inc., a biopharmaceutical company focused on commercializing LipidRescue™ Therapy (LRT), which is a treatment for various drug overdoses and poisonings, announces the completion of a second seed-round of equity financing of $725,000.00.

Read More

Guy Weinberg Presents at EAPCCT

ResQ Pharma, Inc., a biopharmaceutical company focused on ensuring reliable, global use of LipidRescue™ Therapy (LRT), a treatment for various lipophilic drug overdoses & poisonings, today announced that Guy Weinberg, M.D., its co-founder and inventor of LRT will be presenting this Friday, May 27th at the Congress Of The European Association Of Poisons Centres And Clinical Toxicologists

Read More